Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype-Reference-Cited by-同舟云学术

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

Published:2009-11-08 Issue:1 Volume:16 Page:49-58
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Starczynowski Daniel T,Kuchenbauer Florian,Argiropoulos Bob,Sung Sandy,Morin Ryan,Muranyi Andrew,Hirst Martin,Hogge Donna,Marra Marco,Wells Richard A,Buckstein Rena,Lam Wan,Humphries R Keith,Karsan Aly

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2054.pdf

Reference49 articles.

1. Corey, S.J. et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer 7, 118–129 (2007).

2. Nilsson, L. et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q–deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96, 2012–2021 (2000).

3. Nilsson, L. et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 110, 3005–3014 (2007).

4. Thanopoulou, E. et al. Engraftment of NOD/SCID-β2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 103, 4285–4293 (2004).

5. Nimer, S.D. Myelodysplastic syndromes. Blood 111, 4841–4851 (2008).

Cited by 576 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune‐dysregulation harnessing in myeloid neoplasms;Cancer Medicine;2024-09

2. MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response;Frontiers in Oncology;2024-08-02

3. Inflamma-miRs Profile in Myelodysplastic Syndrome Patients;International Journal of Molecular Sciences;2024-06-20

4. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide;Nature Communications;2024-06-20

5. In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms;Blood;2024-06-06